Welcome to our dedicated page for Aimei Health Technology Co SEC filings (Ticker: AFJK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aimei Health Technology Co., Ltd. filings document the regulatory record of a Cayman Islands blank-check company with ordinary shares, units and rights registered for Nasdaq trading. The filings describe SPAC mechanics such as trust-account funding, redemption-related timelines, deadline extensions, shareholder voting procedures and amendments to governing documents.
Recent 8-K, proxy and late-filing records also disclose direct financial obligations, unsecured promissory notes used to fund extension payments, capital-structure terms, material agreements, Nasdaq listing-compliance notices, delayed annual-report reporting and governance matters associated with the company's initial business-combination process.
Aimei Health Technology Co., Ltd notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 because the review of the annual report could not be completed before the due date. The company submitted a Form 12b-25 notification dated April 1, 2026 and invoked Rule 12b-25 relief.
The filing states the company checked the Rule 12b-25(b) boxes that describe (a) the reasons required more effort, and (b) the intent to file within the calendar extension period provided by the rule. Contact listed: Junheng Xie, CEO, phone +86 13758131392.
Aimei Health Technology Co., Ltd extended the deadline to complete its initial business combination with United Hydrogen Group Inc. by one month, moving the termination date from March 6, 2026 to April 6, 2026. To fund this sixteenth extension, a total of $34,330.96 was deposited into the company’s trust account for public shareholders, calculated as the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share for the month.
In connection with the extension, the company issued an unsecured promissory note for $34,330.96 on March 4, 2026 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., with each contributing $17,165.48. The note bears no interest and becomes due when the business combination with United Hydrogen is completed. The payees may convert the note into private units at $10.00 per unit, each unit consisting of one ordinary share and one right to receive one-fifth of one ordinary share, if they notify the company at least two business days before the business combination closes.
Aimei Health Technology Co., Ltd has extended the deadline to complete its initial business combination by one month, moving the termination date from February 6, 2026 to March 6, 2026. To fund this fifteenth monthly extension, an aggregate $34,330.96 was deposited into the company’s trust account for public shareholders.
In connection with this extension, the company issued an unsecured promissory note for $34,330.96 to its sponsor, Aimei Health Ltd, and United Hydrogen Group Inc., each contributing $17,165.48. The note bears no interest and becomes payable when the company consummates its proposed business combination with United Hydrogen. The payees may instead convert the note into private units of Aimei Health at $10.00 per unit immediately before closing, with each unit consisting of one ordinary share and a right to receive one-fifth of one ordinary share.
Mizuho Financial Group, Inc. has filed Amendment No. 3 to its Schedule 13G stating that it now beneficially owns 0 common shares of Aimei Health Technology Co., Ltd., representing 0.0% of the common share class as of 12/31/2025.
The filing reports no sole or shared voting or dispositive power over Aimei’s common shares. Mizuho is identified as a parent holding company, and notes that related entities may have been indirect beneficial owners through a wholly owned subsidiary, Mizuho Securities USA LLC.
Karpus Management, Inc., doing business as Karpus Investment Management, has filed an amended Schedule 13G reporting its beneficial ownership in Aimei Health Technology Co., Ltd. common shares. As of the event date of 12/31/2025, Karpus reports beneficial ownership of 78,075 common shares, representing 1.28% of the class.
Karpus, a New York-based registered investment adviser, reports sole voting and sole dispositive power over all 78,075 shares, with no shared voting or dispositive power. The shares are held in accounts managed by Karpus, and the firm certifies they were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Aimei Health Technology.
Aimei Health Technology Co., Ltd. (AFJK) filed its quarterly report for the period ended September 30, 2025, showing it remains a pre-revenue SPAC earning income from its trust investments. The company reported net income of $352,019 for the quarter and $961,651 for the nine months, driven by $482,171 and $1,546,821 of interest on cash held in the trust account, partially offset by formation and operating costs. As of September 30, 2025, Aimei held $45,443,570 in its trust account and had a working capital deficit of about $2.75 million, with only $2,979 of cash outside the trust. During February 2025, shareholders redeemed 2,904,267 shares for approximately $31.27 million, reducing redeemable shares to 3,995,733. The company has a signed business combination agreement with United Hydrogen, which shareholders later approved, and has repeatedly extended its deadline to complete the merger to December 6, 2025 using unsecured promissory notes from its sponsor and United Hydrogen. Management notes that failure to close a business combination within the allowed period would trigger liquidation, creating substantial doubt about Aimei’s ability to continue as a going concern.
Aimei Health Technology (AFJK) reported shareholder approvals to proceed with its proposed business combination with United Hydrogen and related mergers. Shareholders also approved the issuance of approximately 157,568,133 newly issued ordinary shares in connection with the transaction, as described in the proxy materials.
The Business Combination Proposal and the Merger Proposal each passed with 70.80% of votes cast in favor (3,832,573 for; 1,580,804 against). The Share Issuance Proposal passed with 67.23% in favor (3,639,303 for; 1,774,074 against). An Adjournment Proposal also passed on the same vote totals as the Share Issuance Proposal. As of the record date on September 26, 2025, ordinary shares outstanding were 6,121,733; this is a baseline figure, not the amount being issued.
Following the approvals, 3,950,411 Public Shares were tendered for redemption. The company also outlined an extension meeting to allow more time to close if the business combination is not completed before December 6, 2025.
Aimei Health Technology (AFJK) called an Extraordinary General Meeting on November 26, 2025 to vote on four items that shape its SPAC timeline and governance. The key proposal amends Article 35.2 to extend the deadline to complete a business combination from 24 months to as late as 36 months from the IPO, moving the termination date to December 6, 2026. A related proposal would amend the Trust Agreement to reduce each monthly extension payment by the Sponsor to the lesser of $80,000 for all outstanding Public Shares or $0.033 per outstanding Public Share.
If the article amendment is approved, public shareholders may elect to redeem at a per‑share amount equal to the Trust Account balance divided by Public Shares; this was approximately $11.33 per Public Share as of September 26, 2025. The redemption deadline is 5:00 p.m. ET on November 24, 2025, with delivery via DWAC or certificates. Shareholders will also vote on appointing MaloneBailey, LLP as auditor for 2025 and authorizing potential adjournment to solicit additional votes.
Aimei Health Technology (AFJK) extended its merger deadline by one month after depositing $150,000 into its trust account, moving the termination date from November 6, 2025 to December 6, 2025. This is the twelfth and final extension permitted under its articles.
To fund the deposit, AFJK issued an unsecured $150,000 promissory note on November 4, 2025 to its sponsor and United Hydrogen Group Inc., split $75,000 each. The note bears no interest and becomes due upon consummation of the proposed business combination with United Hydrogen. The payees may convert the note into private units at $10.00 per unit—each unit comprising one ordinary share and one right to receive one-fifth of one ordinary share—immediately prior to closing, with at least two business days’ written notice.
Aimei Health Technology (AFJK) filed a preliminary proxy calling an extraordinary general meeting on November 26, 2025 to vote on four proposals. The key item seeks to amend the Articles to extend the SPAC deadline from 24 months to 36 months, pushing the termination date to December 6, 2026. A related trust amendment would reduce each monthly extension payment to the lesser of $80,000 for all outstanding Public Shares or $0.033 per Public Share, payable by the Sponsor.
If the Article Amendment is approved, Public Shareholders may elect to redeem their shares for their pro rata portion of the trust. As context, the per‑share trust amount was approximately $11.33 as of September 26, 2025, and the redemption deadline is 5:00 p.m. ET on November 24, 2025. Additional proposals ask shareholders to appoint MaloneBailey, LLP as auditor for 2025 and to allow meeting adjournment if needed. The Article Amendment requires at least two‑thirds of votes cast; the other proposals require a simple majority.